Cox-2 inhibitor: An antiinflammatory drug that?selectively?blocks the?cox-2?enzyme. Blocking this enzyme impedes the production of the chemical messengers that cause the pain and swelling of arthritis inflammation.
We aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Case numbers are resurging in parts of the world where the COVID-19 pandemic was waning, falling in places that saw huge surges recently, and just beginning to rise in previously little-impacted parts of the globe.
Studying and analyzing the impact of Coronavirus COVID-19 on the Selective Cox-2 Inhibitors industry, the report provide in-depth analysis and professtional advices on how to face the post COIVD-19 period.
Market Segment by Product Type
Meloxicam
Celecoxib
Etoricoxib
Imrecoxib
Etodolac
Parecoxib
Other
Market Segment by Product Application
Rheumatoid Arthritis
Osteoarthritis
Spondylosis Chronica Ankylopoietica
Other
Finally, the report provides detailed profile and data information analysis of leading company.
Boehringer-Ingelheim
Cipla
Apotex
TerSera Therapeutics
Meda Pharmaceuticals
Iroko Pharmaceuticals
Teva
Breckenridge Pharmaceutical
Yung Shin Pharmaceutical
Glenmark Pharmaceuticals
Pfizer
Bayer
PuraCap Pharmaceutical
Abbott
Mylan
Aurobindo Pharma
Almirall Limited
Novacap
Shire Pharmaceuticals
Lupin Pharmaceuticals
Qilu Pharmaceutical
Geri-Care
Kelun Group
Hengrui pharmaceutical
Merck
Perrigo
Taro Pharmaceuticals
Kopran
Insights and Tools:
Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation.
Product values and regional markets are estimated by market analyst, data analyst and people from related industry, based on companys' revenue and applications market respectively.
The data sources include but not limited to reports of companys,international organizations and governments, MMI market surveys,and related industry news.
Analyses of global market trends, with historical data, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027
The market research includes historical and forecast data from like demand, application details, price trends, and company shares by geography, especially focuses on the key regions like United States, European Union, China, and other regions.
In addition, the report provides insight into main drivers,challenges,opportunities and risk of the market and strategies of suppliers. Key players are profiled as well with their market shares in the global market discussed.
Research Objectives
1.To study and analyze the global Selective Cox-2 Inhibitors consumption (value) by key regions/countries, product type and application, history data from 2017 to 2021, and forecast to 2027.
2.To understand the structure of Selective Cox-2 Inhibitors market by identifying its various subsegments.
3.Focuses on the key global Selective Cox-2 Inhibitors manufacturers, to define, describe and analyze the value, market share, market competition landscape, Porter's five forces analysis, SWOT analysis and development plans in next few years.
4.To analyze the Selective Cox-2 Inhibitors with respect to individual growth trends, future prospects, and their contribution to the total market.
5.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
6.To project the consumption of Selective Cox-2 Inhibitors submarkets, with respect to key regions (along with their respective key countries).
7.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
8.To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
Global Selective Cox-2 Inhibitors Professional Survey Report Report 2022, Forecast to 2027
1 Market Study Overview
1.1 Study Objectives
1.2 Selective Cox-2 Inhibitors Introduce
1.3 Combined with the Analysis of Macroeconomic Indicators
1.4 Brief Description of Research Methods
1.5 Market Breakdown and Data Triangulation
2 Global Trend Summary
2.1 Selective Cox-2 Inhibitors Segment by Type
2.1.1 Meloxicam
2.1.2 Celecoxib
2.1.3 Etoricoxib
2.1.4 Imrecoxib
2.1.5 Etodolac
2.1.6 Parecoxib
2.1.7 Other
2.2 Market Analysis by Application
2.2.1 Rheumatoid Arthritis
2.2.2 Osteoarthritis
2.2.3 Spondylosis Chronica Ankylopoietica
2.2.4 Other
2.3 Global Selective Cox-2 Inhibitors Market Comparison by Regions (2017-2027)
2.3.1 Global Selective Cox-2 Inhibitors Market Size (2017-2027)
2.3.2 North America Selective Cox-2 Inhibitors Status and Prospect (2017-2027)
2.3.3 Europe Selective Cox-2 Inhibitors Status and Prospect (2017-2027)
2.3.4 Asia-pacific Selective Cox-2 Inhibitors Status and Prospect (2017-2027)
2.3.5 South America Selective Cox-2 Inhibitors Status and Prospect (2017-2027)
2.3.6 Middle East & Africa Selective Cox-2 Inhibitors Status and Prospect (2017-2027)
2.4 Basic Product Information
2.4.1 Basic Product Information & Technology Development History
2.4.2 Product Manufacturing Process
2.4.3 Interview with Major Market Participants
2.4.4 High-end Market Analysis and Forecast
2.5 Coronavirus Disease 2019 (Covid-19): Selective Cox-2 Inhibitors Industry Impact
2.5.1 Selective Cox-2 Inhibitors Business Impact Assessment - Covid-19
2.5.2 Market Trends and Selective Cox-2 Inhibitors Potential Opportunities in the COVID-19 Landscape
2.5.3 Measures / Proposal against Covid-19
3 Competition by Manufacturer
3.1 Global Selective Cox-2 Inhibitors Sales and Market Share by Manufacturer (2017-2022)
3.2 Global Selective Cox-2 Inhibitors Revenue and Market Share by Manufacturer (2017-2022)
3.3 Global Selective Cox-2 Inhibitors Industry Concentration Ratio (CR5 and HHI)
3.4 Top 5 Selective Cox-2 Inhibitors Manufacturer Market Share
3.5 Top 10 Selective Cox-2 Inhibitors Manufacturer Market Share
3.6 Date of Key Manufacturers Enter into Selective Cox-2 Inhibitors Market
3.7 Key Manufacturers Selective Cox-2 Inhibitors Product Offered
3.8 Mergers & Acquisitions Planning
4 Analysis of Selective Cox-2 Inhibitors Industry Key Manufacturers
4.1 Boehringer-Ingelheim
4.1.1 Company Details
4.1.2 Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.1.4 Main Business Overview
4.1.5 Boehringer-Ingelheim News
4.2 Cipla
4.2.1 Company Details
4.2.2 Cipla Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.2.3 Cipla Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.2.4 Main Business Overview
4.2.5 Cipla News
4.3 Apotex
4.3.1 Company Details
4.3.2 Apotex Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.3.3 Apotex Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.3.4 Main Business Overview
4.3.5 Apotex News
4.4 TerSera Therapeutics
4.4.1 Company Details
4.4.2 TerSera Therapeutics Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.4.3 TerSera Therapeutics Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.4.4 Main Business Overview
4.4.5 TerSera Therapeutics News
4.5 Meda Pharmaceuticals
4.5.1 Company Details
4.5.2 Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.5.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.5.4 Main Business Overview
4.5.5 Meda Pharmaceuticals News
4.6 Iroko Pharmaceuticals
4.6.1 Company Details
4.6.2 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.6.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.6.4 Main Business Overview
4.6.5 Iroko Pharmaceuticals News
4.7 Teva
4.7.1 Company Details
4.7.2 Teva Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.7.3 Teva Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.7.4 Main Business Overview
4.7.5 Teva News
4.8 Breckenridge Pharmaceutical
4.8.1 Company Details
4.8.2 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.8.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.8.4 Main Business Overview
4.8.5 Breckenridge Pharmaceutical News
4.9 Yung Shin Pharmaceutical
4.9.1 Company Details
4.9.2 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.9.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.9.4 Main Business Overview
4.9.5 Yung Shin Pharmaceutical News
4.10 Glenmark Pharmaceuticals
4.10.1 Company Details
4.10.2 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.10.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.10.4 Main Business Overview
4.10.5 Glenmark Pharmaceuticals News
4.11 Pfizer
4.11.1 Company Details
4.11.2 Pfizer Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.11.3 Pfizer Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.11.4 Main Business Overview
4.11.5 Pfizer News
4.12 Bayer
4.12.1 Company Details
4.12.2 Bayer Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.12.3 Bayer Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.12.4 Main Business Overview
4.12.5 Bayer News
4.13 PuraCap Pharmaceutical
4.13.1 Company Details
4.13.2 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.13.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.13.4 Main Business Overview
4.13.5 PuraCap Pharmaceutical News
4.14 Abbott
4.14.1 Company Details
4.14.2 Abbott Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.14.3 Abbott Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.14.4 Main Business Overview
4.14.5 Abbott News
4.15 Mylan
4.15.1 Company Details
4.15.2 Mylan Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.15.3 Mylan Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.15.4 Main Business Overview
4.15.5 Mylan News
4.16 Aurobindo Pharma
4.16.1 Company Details
4.16.2 Aurobindo Pharma Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.16.3 Aurobindo Pharma Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.16.4 Main Business Overview
4.16.5 Aurobindo Pharma News
4.17 Almirall Limited
4.17.1 Company Details
4.17.2 Almirall Limited Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.17.3 Almirall Limited Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.17.4 Main Business Overview
4.17.5 Almirall Limited News
4.18 Novacap
4.18.1 Company Details
4.18.2 Novacap Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.18.3 Novacap Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.18.4 Main Business Overview
4.18.5 Novacap News
4.19 Shire Pharmaceuticals
4.19.1 Company Details
4.19.2 Shire Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.19.3 Shire Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.19.4 Main Business Overview
4.19.5 Shire Pharmaceuticals News
4.20 Lupin Pharmaceuticals
4.20.1 Company Details
4.20.2 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.20.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.20.4 Main Business Overview
4.20.5 Lupin Pharmaceuticals News
4.21 Qilu Pharmaceutical
4.21.1 Company Details
4.21.2 Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.21.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.21.4 Main Business Overview
4.21.5 Qilu Pharmaceutical News
4.22 Geri-Care
4.22.1 Company Details
4.22.2 Geri-Care Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.22.3 Geri-Care Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.22.4 Main Business Overview
4.22.5 Geri-Care News
4.23 Kelun Group
4.23.1 Company Details
4.23.2 Kelun Group Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.23.3 Kelun Group Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.23.4 Main Business Overview
4.23.5 Kelun Group News
4.24 Hengrui pharmaceutical
4.24.1 Company Details
4.24.2 Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.24.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.24.4 Main Business Overview
4.24.5 Hengrui pharmaceutical News
4.25 Merck
4.25.1 Company Details
4.25.2 Merck Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.25.3 Merck Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.25.4 Main Business Overview
4.25.5 Merck News
4.26 Perrigo
4.26.1 Company Details
4.26.2 Perrigo Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.26.3 Perrigo Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.26.4 Main Business Overview
4.26.5 Perrigo News
4.27 Taro Pharmaceuticals
4.27.1 Company Details
4.27.2 Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.27.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.27.4 Main Business Overview
4.27.5 Taro Pharmaceuticals News
4.28 Kopran
4.28.1 Company Details
4.28.2 Kopran Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.28.3 Kopran Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.28.4 Main Business Overview
4.28.5 Kopran News
5 Global Selective Cox-2 Inhibitors Sales Categorized by Regions
5.1 Global Selective Cox-2 Inhibitors Revenue, Sales and Market Share by Regions
5.1.1 Global Selective Cox-2 Inhibitors Sales and Market Share by Regions (2017-2022)
5.1.2 Global Selective Cox-2 Inhibitors Revenue and Market Share by Regions (2017-2022)
5.2 North America Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
5.3 Europe Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
5.4 Asia-pacific Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
5.5 South America Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
5.6 Middle East & Africa Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
6 North America Selective Cox-2 Inhibitors Market Size Categorized by Countries
6.1 North America Selective Cox-2 Inhibitors Sales, Revenue and Market Share by Countries
6.1.1 North America Selective Cox-2 Inhibitors Sales (Volume) by Countries (2017-2022)
6.1.2 North America Selective Cox-2 Inhibitors Revenue by Countries (2017-2022)
6.1.3 United States Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
6.1.4 Canada Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
6.1.5 Mexico Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
6.2 North America Selective Cox-2 Inhibitors Revenue (Value) by Manufacturers
6.3 North America Selective Cox-2 Inhibitors Sales and Market Share by Type (2017-2022)
6.4 North America Selective Cox-2 Inhibitors Sales Market Share by Application (2017-2022)
7 Europe Selective Cox-2 Inhibitors Market Size Categorized by Countries
7.1 Europe Selective Cox-2 Inhibitors Sales, Revenue and Market Share by Countries
7.1.1 Europe Selective Cox-2 Inhibitors Sales (Volume) by Countries (2017-2022)
7.1.2 Europe Selective Cox-2 Inhibitors Revenue by Countries (2017-2022)
7.1.3 Germany Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
7.1.4 UK Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
7.1.5 France Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
7.1.6 Russia Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
7.1.7 Italy Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
7.1.8 Spain Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
7.2 Europe Selective Cox-2 Inhibitors Revenue (Value) by Manufacturers
7.3 Europe Selective Cox-2 Inhibitors Sales and Market Share by Type (2017-2022)
7.4 Europe Selective Cox-2 Inhibitors Sales Market Share by Application (2017-2022)
8 Asia-Pacific Selective Cox-2 Inhibitors Market Size Categorized by Countries
8.1 Asia-pacific Selective Cox-2 Inhibitors Sales, Revenue and Market Share by Countries
8.1.1 Asia-pacific Selective Cox-2 Inhibitors Sales (Volume) by Countries (2017-2022)
8.1.2 Asia-pacific Selective Cox-2 Inhibitors Revenue by Countries (2017-2022)
8.1.3 China Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
8.1.4 South Korea Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
8.1.5 Japan Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
8.1.6 Australia Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
8.1.7 India Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
8.1.8 Southeast Asia Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
8.2 Asia-pacific Selective Cox-2 Inhibitors Revenue (Value) by Manufacturers
8.3 Asia-pacific Selective Cox-2 Inhibitors Sales and Market Share by Type (2017-2022)
8.4 Asia-pacific Selective Cox-2 Inhibitors Sales Market Share by Application (2017-2022)
9 South America Selective Cox-2 Inhibitors Market Size Categorized by Countries
9.1 South America Selective Cox-2 Inhibitors Sales, Revenue and Market Share by Countries
9.1.1 South America Selective Cox-2 Inhibitors Sales (Volume) by Countries (2017-2022)
9.1.2 South America Selective Cox-2 Inhibitors Revenue by Countries (2017-2022)
9.1.3 Brazil Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
9.2 South America Selective Cox-2 Inhibitors Sales and Market Share by Type (2017-2022)
9.3 South America Selective Cox-2 Inhibitors Sales Market Share by Application (2017-2022)
10 Middle East and Africa Selective Cox-2 Inhibitors Market Size Categorized by Countries
10.1 Middle East and Africa Selective Cox-2 Inhibitors Sales, Revenue and Market Share by Countries
10.1.1 Middle East and Africa Selective Cox-2 Inhibitors Sales (Volume) by Countries (2017-2022)
10.1.2 Middle East and Africa Selective Cox-2 Inhibitors Revenue by Countries (2017-2022)
10.1.3 GCC Countries Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
10.1.4 Turkey Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
10.1.5 Egypt Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
10.1.6 South America Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
10.2 Middle East and Africa Selective Cox-2 Inhibitors Sales and Market Share by Type
10.3 Middle East and Africa Selective Cox-2 Inhibitors Sales Market Share by Application (2017-2022)
11 Global Selective Cox-2 Inhibitors Market Segment by Type
11.1 Global Selective Cox-2 Inhibitors Revenue, Sales and Market Share by Type (2017-2022)
11.1.1 Global Selective Cox-2 Inhibitors Sales and Market Share by Type (2017-2022)
11.1.2 Global Selective Cox-2 Inhibitors Revenue and Market Share by Type (2017-2022)
11.2 Meloxicam Sales Growth Rate and Price
11.2.1 Global Meloxicam Sales Growth Rate (2017-2022)
11.2.2 Global Meloxicam Price (2017-2022)
11.3 Celecoxib Sales Growth Rate and Price
11.3.1 Global Celecoxib Sales Growth Rate (2017-2022)
11.3.2 Global Celecoxib Price (2017-2022)
11.4 Etoricoxib Sales Growth Rate and Price
11.4.1 Global Etoricoxib Sales Growth Rate (2017-2022)
11.4.2 Global Etoricoxib Price (2017-2022)
11.5.1 Global Imrecoxib Sales Growth Rate (2017-2022)
11.5.2 Global Imrecoxib Price (2017-2022)
11.6 Etodolac Sales Growth Rate and Price
11.6.1 Global Etodolac Sales Growth Rate (2017-2022)
11.6.2 Global Etodolac Price (2017-2022)
11.7 Parecoxib Sales Growth Rate and Price
11.7.1 Global Parecoxib Sales Growth Rate (2017-2022)
11.7.2 Global Parecoxib Price (2017-2022)
11.8 Other Sales Growth Rate and Price
11.8.1 Global Other Sales Growth Rate (2017-2022)
11.8.2 Global Other Price (2017-2022)
12 Global Selective Cox-2 Inhibitors Market Segment by Application
12.1 Global Selective Cox-2 Inhibitors Sales Market Share by Application (2017-2022)
12.2 Rheumatoid Arthritis Sales Growth Rate (2017-2022)
12.3 Osteoarthritis Sales Growth Rate (2017-2022)
12.4 Spondylosis Chronica Ankylopoietica Sales Growth Rate (2017-2022)
12.5 Other Sales Growth Rate (2017-2022)
13 Global Selective Cox-2 Inhibitors Market Forecast
13.1 Global Selective Cox-2 Inhibitors Revenue, Sales and Growth Rate (2022-2027)
13.2 Selective Cox-2 Inhibitors Market Forecast by Regions (2022-2027)
13.2.1 North America Selective Cox-2 Inhibitors Market Forecast (2022-2027)
13.2.2 Europe Selective Cox-2 Inhibitors Market Forecast (2022-2027)
13.2.3 Asia-Pacific Selective Cox-2 Inhibitors Market Forecast (2022-2027)
13.2.4 South America Selective Cox-2 Inhibitors Market Forecast (2022-2027)
13.2.5 Middle East & Africa Selective Cox-2 Inhibitors Market Forecast (2022-2027)
13.3 Selective Cox-2 Inhibitors Market Forecast by Type (2022-2027)
13.3.1 Global Selective Cox-2 Inhibitors Sales Forecast by Type (2022-2027)
13.3.2 Global Selective Cox-2 Inhibitors Market Share Forecast by Type (2022-2027)
13.4 Selective Cox-2 Inhibitors Market Forecast by Application (2022-2027)
13.4.1 Global Selective Cox-2 Inhibitors Sales Forecast by Application (2022-2027)
13.4.2 Global Selective Cox-2 Inhibitors Market Share Forecast by Application (2022-2027)
14 Market Analysis
14.1.1 Market overview
14.1.2 Market Opportunities
14.1.3 Market Risk
14.1.4 Market Driving Force
14.1.5 Porter's Five Forces Analysis
14.1.6 SWOT Analysis
15 Selective Cox-2 Inhibitors Industry Related Market Analysis
15.1 Upstream Analysis
15.1.1 Macro Analysis of Upstream Markets
15.1.2 Key Players in Upstream Markets
15.1.3 Upstream Market Trend Analysis
15.1.4 Selective Cox-2 Inhibitors Manufacturing Cost Analysis
15.2 Downstream Market Analysis
15.2.1 Macro Analysis of Down Markets
15.2.2 Key Players in Down Markets
15.2.3 Downstream Market Trend Analysis
15.2.4 Sales Channel, Distributors, Traders and Dealers
List of Tables and Figures
Figure Product Picture Selective Cox-2 Inhibitors
Figure Market Concentration Ratio and Market Maturity Analysis of Selective Cox-2 Inhibitors
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Figure Part of Our External Database
Figure Key Executives Interviewed
Table Global Selective Cox-2 Inhibitors Market Size by Type
Figure Global Market Share of Selective Cox-2 Inhibitors by Type in 2021
Figure Meloxicam Picture
Figure Celecoxib Picture
Figure Etoricoxib Picture
Figure Imrecoxib Picture
Figure Etodolac Picture
Figure Parecoxib Picture
Figure Other Picture
Table Global Selective Cox-2 Inhibitors Market Size (Volume) by Application
Figure Rheumatoid Arthritis Picture
Figure Osteoarthritis Picture
Figure Spondylosis Chronica Ankylopoietica Picture
Figure Other Picture
Table Global Selective Cox-2 Inhibitors Comparison by Regions (M USD) 2017-2027
Figure Global Selective Cox-2 Inhibitors Market Size (Million US$) (2017-2027)
Figure North America Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate (2017-2027)
Figure Europe Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate (2017-2027)
Figure Asia-pacific Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate (2017-2027)
Figure South America Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate (2017-2027)
Figure Middle East & Africa Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate (2017-2027)
Table Business Impact Assessment - Covid-19
Table Market Trends and Selective Cox-2 Inhibitors Potential Opportunities in the COVID-19 Landscape
Table Measures / Proposal against Covid-19
Table Global Selective Cox-2 Inhibitors Sales by Manufacturer (2017-2022)
Figure Global Selective Cox-2 Inhibitors Sales Market Share by Manufacturer in 2021
Table Global Selective Cox-2 Inhibitors Revenue by Manufacturer (2017-2022)
Figure Global Selective Cox-2 Inhibitors Revenue Market Share by Manufacturer in 2021
Table Global Selective Cox-2 Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Figure Top 5 Selective Cox-2 Inhibitors Manufacturer (Revenue) Market Share in 2021
Figure Top 10 Selective Cox-2 Inhibitors Manufacturer (Revenue) Market Share in 2021
Table Date of Key Manufacturers Enter into Selective Cox-2 Inhibitors Market
Table Key Manufacturers Selective Cox-2 Inhibitors Product Type
Table Mergers & Acquisitions Planning
Table Boehringer-Ingelheim Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Boehringer-Ingelheim
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Boehringer-Ingelheim 2017-2022
Table Boehringer-Ingelheim Main Business
Table Boehringer-Ingelheim Recent Development
Table Cipla Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Cipla
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Cipla 2017-2022
Table Cipla Main Business
Table Cipla Recent Development
Table Apotex Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Apotex
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Apotex 2017-2022
Table Apotex Main Business
Table Apotex Recent Development
Table TerSera Therapeutics Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of TerSera Therapeutics
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of TerSera Therapeutics 2017-2022
Table TerSera Therapeutics Main Business
Table TerSera Therapeutics Recent Development
Table Meda Pharmaceuticals Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Meda Pharmaceuticals
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Meda Pharmaceuticals 2017-2022
Table Meda Pharmaceuticals Main Business
Table Meda Pharmaceuticals Recent Development
Table Iroko Pharmaceuticals Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Iroko Pharmaceuticals
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Iroko Pharmaceuticals 2017-2022
Table Iroko Pharmaceuticals Main Business
Table Iroko Pharmaceuticals Recent Development
Table Teva Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Teva
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Teva 2017-2022
Table Teva Main Business
Table Teva Recent Development
Table Breckenridge Pharmaceutical Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Breckenridge Pharmaceutical
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Breckenridge Pharmaceutical 2017-2022
Table Breckenridge Pharmaceutical Main Business
Table Breckenridge Pharmaceutical Recent Development
Table Yung Shin Pharmaceutical Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Yung Shin Pharmaceutical
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Yung Shin Pharmaceutical 2017-2022
Table Yung Shin Pharmaceutical Main Business
Table Yung Shin Pharmaceutical Recent Development
Table Glenmark Pharmaceuticals Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Glenmark Pharmaceuticals
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Glenmark Pharmaceuticals 2017-2022
Table Glenmark Pharmaceuticals Main Business
Table Glenmark Pharmaceuticals Recent Development
Table Pfizer Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Pfizer
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Pfizer 2017-2022
Table Pfizer Main Business
Table Pfizer Recent Development
Table Bayer Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Bayer
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Bayer 2017-2022
Table Bayer Main Business
Table Bayer Recent Development
Table PuraCap Pharmaceutical Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of PuraCap Pharmaceutical
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of PuraCap Pharmaceutical 2017-2022
Table PuraCap Pharmaceutical Main Business
Table PuraCap Pharmaceutical Recent Development
Table Abbott Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Abbott
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Abbott 2017-2022
Table Abbott Main Business
Table Abbott Recent Development
Table Mylan Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Mylan
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Mylan 2017-2022
Table Mylan Main Business
Table Mylan Recent Development
Table Aurobindo Pharma Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Aurobindo Pharma
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Aurobindo Pharma 2017-2022
Table Aurobindo Pharma Main Business
Table Aurobindo Pharma Recent Development
Table Almirall Limited Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Almirall Limited
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Almirall Limited 2017-2022
Table Almirall Limited Main Business
Table Almirall Limited Recent Development
Table Novacap Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Novacap
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Novacap 2017-2022
Table Novacap Main Business
Table Novacap Recent Development
Table Shire Pharmaceuticals Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Shire Pharmaceuticals
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Shire Pharmaceuticals 2017-2022
Table Shire Pharmaceuticals Main Business
Table Shire Pharmaceuticals Recent Development
Table Lupin Pharmaceuticals Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Lupin Pharmaceuticals
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Lupin Pharmaceuticals 2017-2022
Table Lupin Pharmaceuticals Main Business
Table Lupin Pharmaceuticals Recent Development
Table Qilu Pharmaceutical Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Qilu Pharmaceutical
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Qilu Pharmaceutical 2017-2022
Table Qilu Pharmaceutical Main Business
Table Qilu Pharmaceutical Recent Development
Table Geri-Care Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Geri-Care
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Geri-Care 2017-2022
Table Geri-Care Main Business
Table Geri-Care Recent Development
Table Kelun Group Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Kelun Group
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Kelun Group 2017-2022
Table Kelun Group Main Business
Table Kelun Group Recent Development
Table Hengrui pharmaceutical Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Hengrui pharmaceutical
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Hengrui pharmaceutical 2017-2022
Table Hengrui pharmaceutical Main Business
Table Hengrui pharmaceutical Recent Development
Table Merck Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Merck
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Merck 2017-2022
Table Merck Main Business
Table Merck Recent Development
Table Perrigo Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Perrigo
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Perrigo 2017-2022
Table Perrigo Main Business
Table Perrigo Recent Development
Table Taro Pharmaceuticals Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Taro Pharmaceuticals
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Taro Pharmaceuticals 2017-2022
Table Taro Pharmaceuticals Main Business
Table Taro Pharmaceuticals Recent Development
Table Kopran Company Profile
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Kopran
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Kopran 2017-2022
Table Kopran Main Business
Table Kopran Recent Development
Figure Global Selective Cox-2 Inhibitors Sales and Growth Rate (2017-2022)
Figure Global Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2022)
Table Global Selective Cox-2 Inhibitors Sales by Regions (2017-2022)
Figure Global Selective Cox-2 Inhibitors Sales Market Share by Regions in 2021
Table Global Selective Cox-2 Inhibitors Revenue by Regi
Boehringer-Ingelheim
Cipla
Apotex
TerSera Therapeutics
Meda Pharmaceuticals
Iroko Pharmaceuticals
Teva
Breckenridge Pharmaceutical
Yung Shin Pharmaceutical
Glenmark Pharmaceuticals
Pfizer
Bayer
PuraCap Pharmaceutical
Abbott
Mylan
Aurobindo Pharma
Almirall Limited
Novacap
Shire Pharmaceuticals
Lupin Pharmaceuticals
Qilu Pharmaceutical
Geri-Care
Kelun Group
Hengrui pharmaceutical
Merck
Perrigo
Taro Pharmaceuticals
Kopran